GlassScriptPhysician profile
Omar Rafik Kashlan
NPI 1346410594
$4,692.95
in general payments reported to CMS, 2019-2025
32 companies · $936 in 2025
The $936 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $422 · 2021: $505 · 2022: $567 · 2023: $721 · 2024: $1,035 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.62 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $563.32 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $418.32 | 2020-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $404.84 | 2022-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $343.16 | 2019-2025 | |
| Medtronic, INC. | $290.87 | 2025 | Micra, Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.16 | 2020-2025 | Jardiance |
| Abiomed | $259.63 | 2023-2024 | Impella |
| Amgen INC. | $230.57 | 2019-2025 | Repatha, Repatha |
| Stryker Corporation | $187.84 | 2022 | |
| Merck Sharp & Dohme LLC | $179.54 | 2021-2025 | Verquvo, Winrevair |
| Edwards Lifesciences Corporation | $165.97 | 2019-2024 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $158.70 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $147.20 | 2022-2025 | Uptravi, Opsumit |
| Inari Medical, INC. | $131.51 | 2022 | |
| Impulse Dynamics (USA) INC. | $123.94 | 2023 | Optimizer |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $115.59 | 2023 | Ffrct |
| Scpharmaceuticals INC. | $98.44 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $94.41 | 2021-2024 | Camzyos |
| Boston Scientific Corporation | $75.95 | 2019-2025 | Bodyguardian, Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $75.23 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $48.23 | 2024-2025 | |
| Angiodynamics, INC. | $47.94 | 2025 | Angiovac |
| Penumbra, INC. | $44.10 | 2024-2025 | Indigo System, Ruby Coil |
| Becton, Dickinson and Company | $39.75 | 2024 | Hemosphere |
| Esperion Therapeutics, INC. | $36.91 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $30.46 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $23.54 | 2019-2020 | |
| Veryan Medical Incorporated | $23.24 | 2023 | Biomimics 3d Vascular Stent System |
| Amarin Pharma, INC. | $20.18 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.94 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Chiesi USA, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Kashlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.